AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00737568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
Study NCT00737568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF Placebo
Description: TDF placebo tablet administered orally once daily
Study NCT00737568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF Placebo
Description: FTC/TDF placebo tablet administered orally once daily
Study NCT02251561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 109182
Description: Investigational multipurpose contact lens cleaning and disinfecting solution
Study NCT02251561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free Plus
Description: Commercially available multipurpose contact lens cleaning and disinfecting solution
Study NCT02251561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT02251561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study NCT04407026 — intervention group
Intervention type: BIOLOGICAL
Intervention: biofluids
Description: Gingival crevicular fluid, saliva and serum samples were obtained.
Study NCT03222154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental - Shock wave therapy
Description: Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
Study NCT03222154 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Shock wave therapy
Description: Simulation of shock wave therapy
Study NCT00656188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
Study NCT00656188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03207321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Upma
Description: A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
Study NCT03298984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib
Description: IV bolus followed by IV infusion
Study NCT03298984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: continuous infusion
Study NCT03298984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: IV bolus
Study NCT01975519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105 and Pazopanib
Description: Weekly TRC105 in combination with standard dose Pazopanib.
Study NCT02966964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWPUR001
Study NCT02966964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00003234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study NCT01358812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + Panitumumab
Description: PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL\* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
Study NCT04042142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucagon
Description: Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
Study NCT03745365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: loop bipartition
Description: A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.
Study NCT01635673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Whole body vibration exercise 3 times per week
Study NCT03968575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser treatment
Description: sub-threshold micro-pulse laser treatment
Study NCT04199273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation
Description: Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.
Study NCT04199273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
Study NCT01182805 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Echocardiography system Ultra DCI Model 5000
Description: Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
Study NCT01182805 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Echocardiography machine GE Vivid E9
Description: Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
Study NCT01182805 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diastolic function assessment
Description: Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
Study NCT01683006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering.
Study NCT01683006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering.
Study NCT01518998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan , Amlodipine, Placebo
Description: Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
Study NCT01518998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan , Amlodipine, Placebo
Description: Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
Study NCT01518998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fimasartan , Amlodipine, Placebo
Description: Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
Study NCT00570037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent inactivated influenza vaccine
Description: Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
Study NCT02250807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
Study NCT02250807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
Study NCT06389331 — intervention group
Intervention type: OTHER
Intervention: closed the defect with barbed suture
Description: In direct hernia, content was reduced, and the fascia transversalis (pseudo sac) was pulled and incorporated into closure with a non-absorbable polypropylene barbed monofilament size-0 suture
Study NCT03263728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance
Description: Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
Study NCT04715802 — intervention group
Intervention type: PROCEDURE
Intervention: Immediate breast reconstruction with implant
Description: Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.
Study NCT04715802 — intervention group
Intervention type: PROCEDURE
Intervention: delayed breast reconstruction with implant
Description: The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
Study NCT03018171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Intrathecal clonidine addiction
Study NCT03018171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intrathecal
Study NCT02284594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text message
Description: series of text messages regarding influenza vaccination
Study NCT01948622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mulungu
Description: 500 mg/single dose/1 hour before dental surgery
Study NCT01948622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg/single dose/1 hour before dental surgery
Study NCT01652560 — intervention group
Intervention type: DRUG
Intervention: bevacizumab
Description: The patients will be treated with Avastin combined neoadjuvant chemotherapy
Study NCT01023750 — intervention group
Intervention type: DRUG
Intervention: Fenofibrate
Description: Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
Study NCT03007576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RegStem
Description: RegStem, 1.5 ml, one injection
Study NCT01401283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: measurement of cardiac output and pulse pressure variation
Description: hemodynamic optimization according to cardiac index and pulse pressure variation
Study NCT03015389 — intervention group
Intervention type: PROCEDURE
Intervention: Diagnostic Test
Description: WATS3D brush biopsy
Study NCT02374554 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Structured Light Plethysmography (Thora-3Di)
Description: Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
Study NCT02374554 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BCI Capnograph 9004 (Smiths Medical)
Description: Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
Study NCT03520660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: sofosbuvir/velapatasvir combination (Epclusa)
Study NCT01621594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cannon Aquilion ONE CT system
Description: To test the diagnostic accuracy of low-radiation dose CT coronary angiography for detecting significant coronary artery stenosis and to determine the prognostic value of low-radiation dose CT coronary angiography for discriminating patient risk of death or major adverse cardiac events.
Study NCT02181023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
Study NCT04715802 — intervention group
Intervention type: PROCEDURE
Intervention: delayed breast reconstruction with autologous fat transplantation
Description: Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.
Study NCT00737711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: iv 0.6 micrograms/kg every 2 weeks
Study NCT02407405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
Study NCT00615446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248; Gemcitabine
Description: Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
Study NCT04899258 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femtosecond laser assisted LASIK
Description: Refractive surgery
Study NCT01560637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C (treprostinil diolamine)
Description: UT-15C extended release oral tablet three times daily
Study NCT00664313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg po daily for 112 doses (16 weeks)
Study NCT00664313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given daily for 112 doses (16 weeks)
Study NCT00790647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
Study NCT00790647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.0 mg/m2/dose D -6, D-3, D +1, D + 4
Study NCT00790647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 100 mg/m2/dose D -2, D -1
Study NCT00790647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: infusion of previously collected autologous stem cells
Study NCT01824199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
Study NCT00072293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary lymph node dissection
Description: Axillary lymph node dissection
Study NCT00072293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No axillary lymph node dissection
Description: Therapeutic conventional surgery
Study NCT00006441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: 300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
Study NCT00006441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine/Zidovudine
Description: 300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
Study NCT00006441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir mesylate
Description: 1250 mg twice daily for 104 weeks.
Study NCT00006441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelfinavir mesylate
Description: 1250 mg twice daily for 104 weeks.
Study NCT00006441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 7.5 million units twice daily. Treatment will last until conclusion of study.
Study NCT00006441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldesleukin
Description: 7.5 million units twice daily. Treatment will last until conclusion of study.
Study NCT03506451 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Demographics questionnaires and the FACT HN questionnaire
Description: Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
Study NCT01166373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enrollment video
Description: Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
Study NCT01166373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSLF
Description: sacrospinous ligament fixation to suspend the vaginal apex
Study NCT01166373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULS
Description: uterosacral ligament suspension to suspend the vaginal apex
Study NCT01166373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMT
Description: perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
Study NCT01166373 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: usual care both before and after prolapse surgery with respect to pelvic muscle training
Study NCT02684812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Treatment until aneurysm treatment or maximum dosage of 4 gram
Study NCT03464357 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately.
Study NCT02181023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium Bromide
Description: Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
Study NCT01728701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
Study NCT01713660 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: iFS Femtosecond Laser
Description: corneal incisions created by the femtosecond laser
Study NCT01828671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Soy Flour Corn Tortilla
Description: Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.